Generalized Pustular Psoriasis (GPP) Market Analysis for Epidemiology, Pipeline Therapies, and Key Companies Operating in the Market

“generalized pustular psoriasis market”

DelveInsight Generalized Pustular Psoriasis (GPP) – Market Insights, Epidemiology, and Market Forecast – 2032 Report provides an in-depth understanding of the disease, historical and forecast epidemiology as well as market trends of Generalized Pustular Psoriasis in US, EU5 (Germany), France, Italy, Spain, UK) and Japan.

DelveInsight’s Generalized Pustular Psoriasis (GPP) – Market Insights, Epidemiology, and Market Forecast – 2032 AMThe eport provides an in-depth understanding of the disease, historical and forecast epidemiology as well as market trends for generalized pustular psoriasis in the US, EU5 (Germany, France, Italy, Spain, and the UK) and Japan.

The report presents the current treatment practices, emerging drugs, market share of individual therapies, and the current and forecast market size for generalized pustular psoriasis from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practices/algorithm, market drivers, market barriers, and unmet medical needs to nurture the best opportunities and assess the underlying market potential.

Some Key Facts of the Generalized Pustular Psoriasis Market Report:

  • According to a study by Mirza et al. (2021), the annual prevalence of GPP in the French population is estimated to be 1.76 per million. The prevalence in Japan is estimated at 7.46 per million.
  • According to Jordan et al. (2022), the prevalence of GPP ranges from 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect up to 12% of those with plaque psoriasis, and moreover, 70% of patients with GPP also have plaque psoriasis.
  • According to a study by Lebwohl et al. (2022), GPP is a rare disease, with a reported prevalence ranging from 0.01 to 0.02/10000 in France to 5/10000 in Germany.
  • In a study by Twelves et al. (2019), about half of GPP cases were associated with psoriasis vulgaris. GPP is more common in women than in men, with a male to female ratio ranging from 0.5 to 0.9. GPP appears to occur at all ages, and the average age at onset has been found to be between 40 and 50 years
  • According to Noe et al. (2021), GPP is very rare in the United States eg, five study sites (25%) did not have 5 cases of GPP during the 10-year study period. It is more common in women (70%) and is very stressful.

Key Benefits of Generalized Pustular Psoriasis Market Report:

  • This DelveInsight report will help develop business strategies by understanding the trends shaping and driving the Generalized Pustular Psoriasis Market.
  • Organizing sales and marketing efforts by identifying the best opportunities for the generalized pustular psoriasis market
  • To understand the future market competition in the GPP market.

Do you have any questions? Click here to learn more about Generalized market scene of pustular psoriasis

Generalized pustular psoriasis overview

Generalized pustular psoriasis (GPP) is a subtype of pustular psoriasis characterized by sudden and recurrent episodes of high fever, generalized erythematous pustular rash, and painful and sometimes disfiguring skin manifestations with sepsis.

Psoriasis is an autoimmune disease that is clinically classified into two groups: pustular and non-pustular lesions. Non-pustular psoriasis is divided into psoriasis vulgaris (early and late onset), guttate psoriasis, erythrodermic psoriasis, pituitary psoriasis, psoriatic arthritis (PsA), and inverse psoriasis. Pustular psoriasis is also divided into generalized and localized forms.

GPP is a rare, severe and life-threatening form of psoriasis that has been associated with a defect in the signaling of the cytokine interleukin-36 receptor (messenger protein). This is due to the recessive IL36RN gene mutations, systemic symptoms and systemic disorder.

Generalized epidemiological insights of pustular psoriasis:

  • According to a study by Mirza et al. (2021), the annual prevalence of GPP in the French population is estimated to be 1.76 per million. The prevalence in Japan is estimated at 7.46 per million.
  • According to Jordan et al. (2022), the prevalence of GPP ranges from 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect up to 12% of those with plaque psoriasis, and moreover, 70% of patients with GPP also have plaque psoriasis.

Generalized pustular psoriasis epidemiological division

  • generalized pustular psoriasis total population prevalent
  • Pustular Psoriasis Accident
  • General incidence of pustular psoriasis
  • Prevalent generalized pustular psoriasis of a specific age

Pustular Psoriasis Market Overview

The Generalized Pustular Psoriasis Market forecast in the report helps in building a detailed understanding of the historical, current and forecast trend of the market by analyzing the impact of current treatments on the market, unmet needs, drivers, barriers, and demand for better technology.

This part provides an accurate breakdown of the market trend for each marketed drug and late-stage treatment pipeline by evaluating its impact based on annual treatment cost, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, patient segment covered, and year Expected launch, competition with other treatments, brand value, market impact and key opinion leaders’ view. Calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

The GPP market size in the seven major markets is expected to grow at a CAGR of 10.16% for the study period (2017-2028). The current treatment landscape for GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics and phototherapy). In the five EU countries, for GPP, the market is the same as that of the US, with prescriptions for supportive treatments, due to a lack of approved treatment regimens, and together they represented approximately US$20.21 million in 2017. In contrast to the US and EU countries In fifth, the current treatment landscape for GPP in Japan is driven by a number of approved treatments, along with supportive treatment regimens.

Learn more by requesting a form @Generalized market scene of pustular psoriasis

Main companies generalized pustular psoriasis

  • Abvi
  • Kiowa Pharma
  • Novartis
  • Eli Lilly
  • Mitsubishi Tanabe Pharma
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • and others.

Generalized pustular psoriasis treatments

  • Tremvia
  • Skyrzy
  • Humera
  • Lumisev
  • cosnetix
  • Remicade
  • exekizumab
  • and others.

table of contents

  • the main ideas
  • Introduction to the report
  • Executive Summary of Generalized Pustular Psoriasis
  • Disease background and overview
  • Epidemiology and patients
  • Treatments for emerging generalized pustular psoriasis
  • Pustular Psoriasis Market Overview
  • Access to markets and reimbursement for treatments
  • appendix
  • Generalized pustular psoriasis report methodology
  • DelveInsight capabilities
  • disclaimer
  • About DelveInsight

Click here to read more about it generalized pustular psoriasis market

Media connection
The Company’s name: DelveInsight Business Research LLP
contact person: ADIA KOL
E-mail: Send an email
phone: 9193216187
Tabuk:304 S. Jones Blvd #2432
city: Las vigas
condition: Nevada
nation: United State
website: https://www.delveinsight.com/

Leave a Reply

%d bloggers like this: